Last reviewed · How we verify
NCT03741517
Biomarker Study of Pancreatic Neuroendocrine Tumours
trial testing 18F-FDG-PET in Pancreatic Neuroendocrine Tumor in 40 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Uppsala University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 30 January 2019 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- 18F-FDG-PET
- 68Ga-DOTATOC-PET
- Computed tomography
- Core needle biopsy
- Phlebotomy
Conditions studied
- Pancreatic Neuroendocrine Tumor — all drugs for Pancreatic Neuroendocrine Tumor →
Sponsor
Uppsala University
Who can join
18 and older, any sex, with Pancreatic Neuroendocrine Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor hormone secretion. This study aims to characterize how the biology of pancreatic neuroendocrine tumors change over time, measured by; patient symptoms, biochemistry, contrast enhanced computed tomography, DOTATOC-PET, FDG-PET and core needle biopsy with histopathological analysis (Ki67 index and tumor cell differentiation). Uptake on 68Ga-DOTATOC and 18F-FDG-PET will be correlated directly to tumor cell proliferation rate. Fraction of patients with spatial heterogeneity in DOTATOC as well as FDG uptake as well as metachronous changes in all collected data will be documented. Biomaterial from whole blood and core needle biopsies will be characterized on the molecular level, and those findings will be integrated to the above specified clinical parameters.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Factors associated with grade progression in pancreatic neuroendocrine tumors.
Wang SJ, Kidder W, Joseph NM, Le BK, et al · · 2025 · cited 4× · PMID 39813097 · DOI 10.1530/erc-24-0203
Verify or expand the search:
- PubMed search for NCT03741517
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 18F-FDG-PET
Trials testing the same drug.
- NCT03130205 — Biomarker Study in Pancreatic Neuroendocrine Tumours · unknown
Other recruiting trials for Pancreatic Neuroendocrine Tumor
Currently open trials in the same condition.
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
- NCT07328607 — Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy · NA · recruiting
- NCT07273409 — Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not · NA · recruiting
- NCT06406387 — ATRX/DAXX in EUS-FNB Specimens of Pan-NETs · active not recruiting
- NCT06141369 — Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) · NA · recruiting
Other Uppsala University trials
Trials by the same sponsor.
- NCT07517185 — The HIt HArd and hiT Early in Multiple Sclerosis Trial · Phase 2 · not yet recruiting
- NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
- NCT07461636 — Robotic-Assisted Pedicle Screw Placement in Spine Surgery · recruiting
- NCT07273409 — Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not · NA · recruiting
- NCT07352683 — Open TAP-block in Pediatric Abdominal Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03741517 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uppsala University
- Last refreshed: 18 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03741517.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing